Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Specific Antiviral Drugs For COVID 19 Market Size Changed, over the years?

In recent times, significant growth has been observed in the market size for specific antiviral drugs for Covid-19. It is projected to rise from $13 billion in 2024 to $15.23 billion in 2025, representing a compound annual growth rate (CAGR) of 17.1%. This significant growth during the historic period can be attributed to factors such as an increase in hospital admissions due to severe cases, enhanced government funding allocated towards antiviral research, growing preference for targeted therapeutics over generic treatments, higher awareness regarding early antiviral intervention, and escalating collaborations among pharmaceutical firms.

How Much Will the Specific Antiviral Drugs For COVID 19 Market Be Worth in 2029?

The market for specific antiviral drugs for Covid-19 is predicted to experience swift expansion in the upcoming years, rising to a valuation of $28.43 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 16.9%. The progress projected within this period is due to factors like heightened emphasis on pandemic readiness, an increase in clinical trials, a surge in demand for effective COVID-19 treatment alternatives, a rise in the occurrence of COVID-19 variants, and increased acceptance of oral antiviral treatments. The forecast period will also see major trends such as the development of broad-spectrum antiviral formulations, the application of artificial intelligence in drug discovery, advancements in customized antiviral therapies, innovation in combined therapy strategies, and the incorporation of genomic information to address viral mutations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

Which is the Largest Company in the Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

What Are the Main Market Drivers in the Specific Antiviral Drugs For COVID 19 Industry?

The increasing incidence of COVID-19 is projected to fuel the expansion of the specific antiviral drugs for the COVID-19 market. COVID-19 cases are those individuals who have been diagnosed with the SARS-CoV-2 virus, the causative agent of COVID-19. The escalating number of cases can be attributed to the emergence of new variants, which are more transmissible and can somewhat skirt immunity granted by vaccinations or prior infections. Specialized antiviral medications for COVID-19 serve to lessen the severity and duration of the disease, improving patient prognosis and reducing the overall COVID-19 case load. For example, the Centers for Disease Control and Prevention, a US governmental agency, reported in May 2023 that the average number of COVID-19 deaths accompanied by additional causes had 4.5 contributing conditions listed in 2022, a rise from 4.2 in 2021. Consequently, the uptick in COVID-19 cases spurs the growth of the specific antiviral drugs for the COVID-19 market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

How Is the Specific Antiviral Drugs For COVID 19 Market Segments Structured?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

What Strategic Trends Are Transforming the Specific Antiviral Drugs For COVID 19 Market?

Key players in the COVID-19 specific antiviral drugs market are concentrating their efforts on the development of novel treatments, like oral antiviral therapies, to improve the accessibility and efficacy of treatment. These are drugs ingested orally to curb the spread of viruses, such as COVID-19, offering an efficient and straightforward option for treatment. For example, Lupin Limited, a pharmaceutical company based in India, introduced their antiviral drug Molnupiravir, under the brand name Molnulup, in January 2022. It’s designed for adults with mild to moderate COVID-19 who are at a higher risk of progressing to severe disease. Molnupiravir functions by stopping the replication of the SARS-CoV-2 virus, consequently lowering the viral load and lessening the disease’s severity. It proves most effective when initiated within the first five days of showing symptoms and is particularly useful for people with coexisting conditions such as obesity, old age, diabetes, or cardiovascular disease.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

Which Global Regions Offer the Highest Growth in the Specific Antiviral Drugs For COVID 19 Market?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24713

This Report Delivers Insight On:

1. How big is the specific antiviral drugs for covid 19 market, and how is it changing globally?

2. Who are the major companies in the specific antiviral drugs for covid 19 market, and how are they performing?

3. What are the key opportunities and risks in the specific antiviral drugs for covid 19 market right now?

4. Which products or customer segments are growing the most in the specific antiviral drugs for covid 19 market?

5. What factors are helping or slowing down the growth of the specific antiviral drugs for covid 19 market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model